Biotech not discouraged by Merck protease inhibitor setback
Biotech not discouraged by Merck protease inhibitor setback
The biotech contenders in the HIV protease inhibitor race haven't been discouraged by recent reports that virus levels in patients treated with Merck's L-735,524 compound have returned to baseline levels.
Merck's problems with its lead compound were totally predictable,
